1
Avinash G Thombre: Dispensing device containing a hydrophobic medium. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, July 11, 1995: US05431921 (347 worldwide citation)

A device for the controlled delivery of an insoluble or partially aqueous insoluble beneficial agent to an aqueous containing environment. The device comprises a shaped wall that surrounds and defines an internal reservoir. The wall is formed at least in part of a sintered polymer microporous membra ...


2

3
Robert L Dow, Kevin Koch, Gary R Schulte: 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, January 14, 1997: US05593997 (138 worldwide citation)

Certain 4-aminopyrazolo[3,4-d]pyrimidine compounds, and their pharmaceutically-acceptable salts and prodrugs, are inhibitors of tyrosine kinase enzymes and are useful for immunoregulation and for the treatment of cancer, angiogenesis and atherosclerosis.


4
Andrew S Bell, David Brown, Nicholas K Terrett: Pyrazolopyrimidinone antianginal agents. Pfizer, Peter C Richardson, Gregg C Benson, James T Jones, October 5, 1993: US05250534 (79 worldwide citation)

Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalk ...


5
Thomas Francis Dolan, Michael John Humphrey, Donald John Nichols: Pharmaceutical formulations containing darifenacin. Pfizer, Peter C Richardson, Gregg C Benson, James T Jones, August 22, 2000: US06106864 (78 worldwide citation)

There is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, characterized in that the dosage form is adapte ...


6
Kimberly O Cameron, Paul A Dasilva Jardine, Robert L Rosati: 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis. Pfizer, Peter C Richardson, Gregg C Benson, Mervin E Brokke, September 3, 1996: US05552412 (71 worldwide citation)

Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.


7
John R Cardinal, Scott M Herbig, Richard W Korsmeyer, Jeelin Lo, Kelly L Smith, Avinash G Thombre: Asymmetric membranes in delivery devices. Pfizer, Peter C Richardson, Gregg C Benson, A Dean Olson, December 16, 1997: US05698220 (70 worldwide citation)

A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.


8
Leah E Appel, William J Curatolo, Scott M Herbig, James A S Nightingale, Avinash G Thombre: Controlled release by extrusion of solid amorphous dispersions of drugs. Pfizer, Peter C Richardson, Gregg C Benson, James T Jones, March 16, 2004: US06706283 (70 worldwide citation)

Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of tre ...


9
Michael L Francoeur, Russell O Potts: Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris. Pfizer, Peter C Richardson, Gregg C Benson, February 21, 1995: US05391548 (66 worldwide citation)

A transdermal flux enhancing pharmaceutical composition for transdermal administration to a human or lower animal subject comprising a safe and effective amount of a pharmacologically active compound or a prodrug thereof, an aqueous solvent system comprising from about 15 to 75% by volume of one or ...


10
William J Curatolo, Hylar L Friedman, Richard W Korsmeyer, Steven R LeMott: Controlled-release dosage forms of Azithromycin. Pfizer, Peter C Richardson, Gregg C Benson, James T Jones, May 30, 2000: US06068859 (66 worldwide citation)

A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in ...